ABS Compliance & Monitoring Bodies

Global information platform established under the Nagoya Protocol for ABS legislation, national focal point and competent authority listings, and implementation records.

UN Convention on Biological Diversity secretariat supporting implementation of the Nagoya Protocol and coordinating ABS policy, compliance processes, and party information exchange.

German federal authority serving as a competent national authority contact for Nagoya Protocol implementation functions and ABS coordination in Germany.

Filament Health is a Canadian natural-psychedelics drug-development company and a leading supplier of pharmaceutical-grade botanical psilocybin. Its patented lead candidate, PEX010, is a standardised natural psilocybin drug candidate used across more than 80 academic and clinical studies worldwide, including Germany's compassionate-use programme and numerous depression, PTSD and cancer-distress trials. On 30 April 2026, Filament was acquired by and became a wholly-owned subsidiary of Red Light Holland (Cboe CA: TRIP), which now advances the PEX010 supply business and a patent portfolio of 76 issued patents across 15 families. In July 2026 Filament agreed to supply PEX010 for an ARQ National Psychotrauma Centre veterans-PTSD study in the Netherlands.

UK enforcement body appointed by Defra to enforce Nagoya Protocol ABS compliance regulations for users of genetic resources and associated traditional knowledge.

Canadian drug development company active in iboga/ibogaine sourcing and extraction, with public claims of Nagoya-compliant supply and reciprocal benefit-sharing structures in Gabon.